Compare REVB & VMAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REVB | VMAR |
|---|---|---|
| Founded | 2020 | 1995 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1M | 4.9M |
| IPO Year | N/A | 2020 |
| Metric | REVB | VMAR |
|---|---|---|
| Price | $0.86 | $0.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 99.4K | ★ 27.4M |
| Earning Date | 11-06-2025 | 01-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,832,556.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 395.85 |
| 52 Week Low | $0.83 | $0.23 |
| 52 Week High | $60.48 | $39.00 |
| Indicator | REVB | VMAR |
|---|---|---|
| Relative Strength Index (RSI) | 36.34 | 33.06 |
| Support Level | $0.93 | $0.23 |
| Resistance Level | $0.90 | $0.33 |
| Average True Range (ATR) | 0.07 | 0.15 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 3.46 | 0.68 |
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
Vision Marine Technologies Inc designs and manufactures electric outboard powertrain systems, power boats, related technology, and rents electric boats. Its models include Bruce 22, Fantail 217, VX Electric Pontoon, Volt 180, Phantom, and others. The company provides goods and services for the recreational boating market and focuses on electric outboard powertrain systems, electric power boats, and the renting of electric boats through its subsidiary. It sells boats, parts, and accessories and offers services related to recreational boating, including boats with internal combustion engines and electric propulsion. The company operates in two reportable segments, the sale of electric boats and the rental of electric boats, and generates a substantial portion of its revenue from the USA.